Molecular imaging with PET-computerized tomography (PET-CT) plays an important role in oncology. There is current and evolving evidence supporting the use of fluorodeoxyglucose (FDG) and non-FDG tracers in assessment patients with hepatobiliary and pancreatic cancers in various clinical scenarios. In this chapter, we discuss the advantages and limitations of FDG and non-FDG PET-CT in the management of patients with hepatobiliary and pancreatic cancers.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cpet.2022.03.007 | DOI Listing |
Publication Analysis
Top Keywords
hepatobiliary pancreatic
12
pet-computerized tomography
8
fdg non-fdg
8
patients hepatobiliary
8
pancreatic cancers
8
18f-fluorodeoxyglucose-pet-computerized tomography
4
tomography non-fluorodeoxyglucose
4
non-fluorodeoxyglucose pet-computerized
4
tomography hepatobiliary
4
pancreatic malignancies
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!